ホーム › 食道癌 › カリフォルニア州 › Los Angeles
Los Angeles、CAにおける食道癌の臨床試験
Los Angelesとその周辺地域（約30マイル以内）の拠点で、食道癌に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
被験者募集中第1/2相
- UCLA Hematology/Oncology - Santa Monica ( Site 4905), Los Angeles
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- Ronald Reagan UCLA Medical Center, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- University of Southern California, Los Angeles
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
被験者募集中第3相
- UCLA, Los Angeles
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
被験者募集中第1/2相
- UCLA Hematology/Oncology - Santa Monica ( Site 8905), Los Angeles
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
被験者募集中第1/2相
- UCLA Hematology/Oncology - Santa Monica ( Site 6905), Los Angeles
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Ronald Reagan UCLA Medical Center, Los Angeles
- The Regents of the University of California, Los Angeles
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
被験者募集中
- Oncology Institute for Hope and Innovation, Los Angeles
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
被験者募集中
- Cedars-Sinai Medical Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- University of Southern California, Los Angeles
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
被験者募集中第4相
- Cedars-Sinai Medical Center, Los Angeles
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
被験者募集中観察研究健康なボランティア歓迎
- UCLA Medical Center, Los Angeles
他の都市における食道癌の試験
- Houston, TX36件の研究
- Boston, MA23件の研究
- New York City, NY22件の研究
- Nashville, TN19件の研究
- St. Louis, MO17件の研究
- Pittsburgh, PA15件の研究
- Baldwin Park, CA14件の研究
- Grand Rapids, MI14件の研究
- Philadelphia, PA13件の研究
- San Antonio, TX12件の研究
- Dallas, TX11件の研究
- Arlington, VA11件の研究
Los Angelesにおける他の研究
- 非小細胞肺癌87件の研究
- がん（全種類）74件の研究
- 乳がん73件の研究
- 前立腺がん61件の研究
- 大腸癌59件の研究
- 転移性癌57件の研究
- 卵巣がん50件の研究
- 肺がん45件の研究
- 頭頸部扁平上皮癌42件の研究
- 膵臓がん35件の研究
- 子宮内膜がん34件の研究
- 悪性黒色腫34件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。